NCT06613139

Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers

An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2- Period, Crossover Study to Evaluate Bioequivalence Between YHP2305 and YHR2404 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

An open-label, randomized, single-dose, oral administration, 2-sequence, 2- period, crossover study to evaluate bioequivalence between YHP2305 and YHR2404 in healthy subjects

Detailed description

Subjects in group A will be administered comparator and YHP2305 by crossover design on day 1, 8. Subjects in group B will be administered YHP2305 and comparator by crossover design on day 1, 8.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	YHP2305	Test drug: YHP2305 Comparator: YHR2404
DRUG	YHR2404	Test drug: YHP2305 comparator: YHR2404

Timeline

• Start date: 2024-10-06
• Primary completion: 2024-10-15
• Completion: 2024-10-24
• First posted: 2024-09-25
• Last updated: 2024-11-15

Locations

1 site across 1 country: South Korea